|
US511A
(en)
*
|
|
1837-12-15 |
|
Improved mode of coloring and finishing leather |
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4440859A
(en)
|
1977-05-27 |
1984-04-03 |
The Regents Of The University Of California |
Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
|
|
US4704362A
(en)
|
1977-11-08 |
1987-11-03 |
Genentech, Inc. |
Recombinant cloning vehicle microbial polypeptide expression
|
|
GR73675B
(enExample)
|
1978-12-22 |
1984-03-29 |
Biogen Inc |
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
US4530901A
(en)
|
1980-01-08 |
1985-07-23 |
Biogen N.V. |
Recombinant DNA molecules and their use in producing human interferon-like polypeptides
|
|
CA1200773A
(en)
|
1980-02-29 |
1986-02-18 |
William J. Rutter |
Expression linkers
|
|
US4554101A
(en)
|
1981-01-09 |
1985-11-19 |
New York Blood Center, Inc. |
Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
|
|
US4678751A
(en)
|
1981-09-25 |
1987-07-07 |
Genentech, Inc. |
Hybrid human leukocyte interferons
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
US4766075A
(en)
|
1982-07-14 |
1988-08-23 |
Genentech, Inc. |
Human tissue plasminogen activator
|
|
US4582800A
(en)
|
1982-07-12 |
1986-04-15 |
Hoffmann-La Roche Inc. |
Novel vectors and method for controlling interferon expression
|
|
US4757006A
(en)
|
1983-10-28 |
1988-07-12 |
Genetics Institute, Inc. |
Human factor VIII:C gene and recombinant methods for production
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
JPS60188070A
(ja)
|
1984-03-09 |
1985-09-25 |
Kunio Yamane |
シグナルペプチドをコードするｄｎａ
|
|
GB8412517D0
(en)
|
1984-05-16 |
1984-06-20 |
Nagai K |
Recombinant fusion proteins
|
|
CA1282721C
(en)
|
1984-06-04 |
1991-04-09 |
Bernard Roizman |
Herpes simplex virus as a vector
|
|
US4677063A
(en)
|
1985-05-02 |
1987-06-30 |
Cetus Corporation |
Human tumor necrosis factor
|
|
CA1341423C
(en)
|
1984-10-31 |
2003-03-04 |
Paul A. Luciw |
Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
|
|
US4945050A
(en)
|
1984-11-13 |
1990-07-31 |
Cornell Research Foundation, Inc. |
Method for transporting substances into living cells and tissues and apparatus therefor
|
|
US5036006A
(en)
|
1984-11-13 |
1991-07-30 |
Cornell Research Foundation, Inc. |
Method for transporting substances into living cells and tissues and apparatus therefor
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
IL79289A
(en)
|
1985-07-05 |
1992-01-15 |
Whitehead Biomedical Inst |
Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
|
|
KR890003620Y1
(ko)
|
1985-07-25 |
1989-05-27 |
삼성전자주식회사 |
전자레인지의 파워릴레이 구동회로
|
|
CA1293460C
(en)
|
1985-10-07 |
1991-12-24 |
Brian Lee Sauer |
Site-specific recombination of dna in yeast
|
|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
|
US4810648A
(en)
|
1986-01-08 |
1989-03-07 |
Rhone Poulenc Agrochimie |
Haloarylnitrile degrading gene, its use, and cells containing the gene
|
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5084384A
(en)
|
1987-04-23 |
1992-01-28 |
Monsanto Company |
Secretion of insulin-like growth factor-I
|
|
US6093699A
(en)
|
1987-07-09 |
2000-07-25 |
The University Of Manitoba |
Method for gene therapy involving suppression of an immune response
|
|
US5017478A
(en)
|
1987-07-16 |
1991-05-21 |
Berlex Laboratories, Inc. |
Transfected cells containing plasmids having genes oriented in opposing directions and methods of using
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
NZ226414A
(en)
|
1987-10-02 |
1992-07-28 |
Genentech Inc |
Cd4 peptide adhesion variants and their preparation and use
|
|
ZA887365B
(en)
|
1987-10-02 |
1990-05-30 |
Genentech Inc |
Adheson variants
|
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
|
US6710169B2
(en)
|
1987-10-02 |
2004-03-23 |
Genentech, Inc. |
Adheson variants
|
|
US6018026A
(en)
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
|
ES2092468T3
(es)
|
1988-01-22 |
1996-12-01 |
Zymogenetics Inc |
Metodos para producir analogos de receptores secretados.
|
|
US5567584A
(en)
|
1988-01-22 |
1996-10-22 |
Zymogenetics, Inc. |
Methods of using biologically active dimerized polypeptide fusions to detect PDGF
|
|
US5716826A
(en)
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
|
US5614404A
(en)
|
1988-06-10 |
1997-03-25 |
Theriod Biologics, Incorporated |
Self-assembled, defective, non-self-propagating lentivirus particles
|
|
US5284768A
(en)
|
1988-08-24 |
1994-02-08 |
Sanofi |
Signal peptide, DNA sequences coding for the latter, expression vectors carrying one of these sequences, gram-negative bacteria transformed by these vectors, and process for the periplasmic production of a polypeptide
|
|
US5349052A
(en)
|
1988-10-20 |
1994-09-20 |
Royal Free Hospital School Of Medicine |
Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
|
|
US6685941B1
(en)
|
1988-11-23 |
2004-02-03 |
The Regents Of The University Of Michigan |
Methods of treating autoimmune disease via CTLA-4Ig
|
|
DE3901681A1
(de)
|
1989-01-21 |
1990-07-26 |
Behringwerke Ag |
Signalpeptid fuer die sekretion von peptiden in escherichia coli, verfahren zu seiner gewinnung und seine verwendung
|
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
|
US5082767A
(en)
|
1989-02-27 |
1992-01-21 |
Hatfield G Wesley |
Codon pair utilization
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5122614A
(en)
|
1989-04-19 |
1992-06-16 |
Enzon, Inc. |
Active carbonates of polyalkylene oxides for modification of polypeptides
|
|
US5672683A
(en)
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
|
DE69033911D1
(de)
|
1989-10-24 |
2002-03-14 |
Chiron Corp |
System zur freisetzung von infektiösen proteinen
|
|
EP0800830A3
(en)
|
1989-11-03 |
1999-03-17 |
Vanderbilt University |
Method of in vivo delivery of functioning foreign genes
|
|
US5697901A
(en)
|
1989-12-14 |
1997-12-16 |
Elof Eriksson |
Gene delivery by microneedle injection
|
|
US5672510A
(en)
|
1990-01-19 |
1997-09-30 |
Genetic Therapy, Inc. |
Retroviral vectors
|
|
US7070776B1
(en)
|
1990-03-26 |
2006-07-04 |
Bristol-Myers Squibb Company |
Methods for blocking binding of CD28 receptor to B7
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
|
SE9003978D0
(sv)
|
1990-12-13 |
1990-12-13 |
Henrik Garoff |
Dna expressionssystem baserade paa ett virus replikon
|
|
CZ194693A3
(en)
|
1991-03-19 |
1994-03-16 |
Cytrx Corp |
Copolymers polyoxypropylene/polyoxyethylene with enhanced biological activity
|
|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
US5770197A
(en)
|
1991-06-27 |
1998-06-23 |
Bristol-Myers Squibb Company |
Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
|
|
CA2580812A1
(en)
|
1991-06-27 |
1993-01-07 |
Bristol-Myers Squibb Company |
Ctla4 receptor, fusion proteins containing it and uses thereof
|
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
|
US6090914A
(en)
|
1991-06-27 |
2000-07-18 |
Bristol-Myers Squibb Company |
CTLA4/CD28Ig hybrid fusion proteins and uses thereof
|
|
US5506098A
(en)
|
1991-09-04 |
1996-04-09 |
Daikin Industries, Ltd. |
In situ hybridization method
|
|
US5635532A
(en)
|
1991-10-21 |
1997-06-03 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
|
|
DE69333580D1
(de)
|
1992-04-07 |
2004-09-09 |
Univ Michigan |
Immunregulation über die cd28-route
|
|
US5792751A
(en)
|
1992-04-13 |
1998-08-11 |
Baylor College Of Medicine |
Tranformation of cells associated with fluid spaces
|
|
US5587308A
(en)
|
1992-06-02 |
1996-12-24 |
The United States Of America As Represented By The Department Of Health & Human Services |
Modified adeno-associated virus vector capable of expression from a novel promoter
|
|
WO1993025673A1
(en)
|
1992-06-04 |
1993-12-23 |
The Regents Of The University Of California |
In vivo gene therapy with intron-free sequence of interest
|
|
EP0671926B1
(en)
|
1992-08-11 |
2002-11-13 |
President And Fellows Of Harvard College |
Immunomodulatory peptides
|
|
WO1994012520A1
(en)
|
1992-11-20 |
1994-06-09 |
Enzon, Inc. |
Linker for linked fusion polypeptides
|
|
DE69329974T2
(de)
|
1992-12-04 |
2001-07-19 |
Medical Research Council, London |
Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
|
|
US5633234A
(en)
|
1993-01-22 |
1997-05-27 |
The Johns Hopkins University |
Lysosomal targeting of immunogens
|
|
US5773253A
(en)
|
1993-01-22 |
1998-06-30 |
Bristol-Myers Squibb Company |
MYPPPY variants of CTL A4 and uses thereof
|
|
EP0621337A1
(en)
|
1993-01-25 |
1994-10-26 |
American Cyanamid Company |
Codon optimized DNA sequence for insect toxin AaIT
|
|
US5593972A
(en)
|
1993-01-26 |
1997-01-14 |
The Wistar Institute |
Genetic immunization
|
|
US5981505A
(en)
|
1993-01-26 |
1999-11-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for delivery of genetic material
|
|
US6482919B2
(en)
|
1993-02-01 |
2002-11-19 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
AU692152B2
(en)
|
1993-03-17 |
1998-06-04 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
|
|
TW404844B
(en)
|
1993-04-08 |
2000-09-11 |
Oxford Biosciences Ltd |
Needleless syringe
|
|
ES2181717T3
(es)
|
1993-04-21 |
2003-03-01 |
Pasteur Institut |
Implante biocompatible para la expresion y la secrecion in vivo de un compuesto terapeutico.
|
|
US5591601A
(en)
|
1993-05-14 |
1997-01-07 |
Ohio University Edison Animal Biotechnology Institute |
DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system
|
|
US6133028A
(en)
|
1993-05-28 |
2000-10-17 |
Transgene S.A. |
Defective adenoviruses and corresponding complementation lines
|
|
US5679647A
(en)
|
1993-08-26 |
1997-10-21 |
The Regents Of The University Of California |
Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
|
|
US5804566A
(en)
|
1993-08-26 |
1998-09-08 |
The Regents Of The University Of California |
Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
|
|
US5830877A
(en)
|
1993-08-26 |
1998-11-03 |
The Regents Of The University Of California |
Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
|
|
US5849719A
(en)
|
1993-08-26 |
1998-12-15 |
The Regents Of The University Of California |
Method for treating allergic lung disease
|
|
US5426039A
(en)
|
1993-09-08 |
1995-06-20 |
Bio-Rad Laboratories, Inc. |
Direct molecular cloning of primer extended DNA containing an alkane diol
|
|
WO1995007994A2
(en)
|
1993-09-15 |
1995-03-23 |
Viagene, Inc. |
Recombinant alphavirus vectors
|
|
US6107095A
(en)
|
1993-11-26 |
2000-08-22 |
Mazurkiewicz; Marian |
Method for introducing substances into living cells and tissues
|
|
US5580766A
(en)
|
1994-01-14 |
1996-12-03 |
Alexion Pharmaceuticals, Inc. |
Retroviral vector particles for transducing non-proliferating cells
|
|
ES2192573T3
(es)
|
1994-01-21 |
2003-10-16 |
Powderject Vaccines Inc |
Instrumento de deposito de genes mediante arrastre gaseoso.
|
|
US6335160B1
(en)
|
1995-02-17 |
2002-01-01 |
Maxygen, Inc. |
Methods and compositions for polypeptide engineering
|
|
US6117679A
(en)
|
1994-02-17 |
2000-09-12 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
|
US6077835A
(en)
|
1994-03-23 |
2000-06-20 |
Case Western Reserve University |
Delivery of compacted nucleic acid to cells
|
|
US5739118A
(en)
|
1994-04-01 |
1998-04-14 |
Apollon, Inc. |
Compositions and methods for delivery of genetic material
|
|
GB9406974D0
(en)
|
1994-04-08 |
1994-06-01 |
Pharmaceutical Proteins Ltd |
Transgenic production
|
|
US5658785A
(en)
|
1994-06-06 |
1997-08-19 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
JP3816518B2
(ja)
|
1994-06-10 |
2006-08-30 |
ジェンベク、インコーポレイティッド |
相補的なアデノウイルスベクター系と細胞系
|
|
US5601820A
(en)
|
1994-07-07 |
1997-02-11 |
Children's Hospital Of Philadelphia |
Compositions and methods of making and using human full length TRK-B
|
|
US5855579A
(en)
*
|
1994-07-15 |
1999-01-05 |
Smith & Nephew, Inc. |
Cannulated modular intramedullary nail
|
|
EP1181937A3
(en)
|
1994-08-09 |
2004-02-04 |
Cytrx Corporation |
Novel vaccine adjuvant and vaccine
|
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
|
GB9502879D0
(en)
|
1995-02-14 |
1995-04-05 |
Oxford Biosciences Ltd |
Particle delivery
|
|
US6127525A
(en)
|
1995-02-21 |
2000-10-03 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral coat protein and methods of using same
|
|
US5750340A
(en)
|
1995-04-07 |
1998-05-12 |
University Of New Mexico |
In situ hybridization solution and process
|
|
US5922687A
(en)
|
1995-05-04 |
1999-07-13 |
Board Of Trustees Of The Leland Stanford Junior University |
Intracellular delivery of nucleic acids using pressure
|
|
US5525510A
(en)
|
1995-06-02 |
1996-06-11 |
Agracetus, Inc. |
Coanda effect gene delivery instrument
|
|
ATE288487T1
(de)
|
1995-06-05 |
2005-02-15 |
Univ Washington |
Verfahren zur verlängerung der expression eines interessierenden gens unter verwendung von löslichen ctla4 molekülen
|
|
US5993800A
(en)
|
1995-06-05 |
1999-11-30 |
Bristol-Myers Squibb Company |
Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
|
|
US5811406A
(en)
|
1995-06-07 |
1998-09-22 |
Regents Of The University Of California |
Dry powder formulations of polynucleotide complexes
|
|
US5668110A
(en)
|
1995-06-07 |
1997-09-16 |
Affymax Technologies N.V. |
Peptides and compounds that bind to the IL-5 receptor
|
|
FR2737222B1
(fr)
|
1995-07-24 |
1997-10-17 |
Transgene Sa |
Nouveaux vecteurs viraux et lignee pour la therapie genique
|
|
AU6691496A
(en)
|
1995-08-01 |
1997-02-26 |
Advanced Therapies, Inc. |
Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
|
|
US5966560A
(en)
*
|
1995-08-29 |
1999-10-12 |
Minolta Co., Ltd. |
Image forming apparatus with enhanced pretransfer erasing
|
|
US5801030A
(en)
|
1995-09-01 |
1998-09-01 |
Genvec, Inc. |
Methods and vectors for site-specific recombination
|
|
US7041634B2
(en)
|
1995-09-27 |
2006-05-09 |
Emory University |
Method of inhibiting immune system destruction of transplanted viable cells
|
|
WO1997011607A1
(en)
|
1995-09-27 |
1997-04-03 |
Emory University |
Method of inhibiting immune system destruction of transplanted viable cells
|
|
KR970029803A
(ko)
|
1995-11-03 |
1997-06-26 |
김광호 |
반도체 메모리장치의 프리차지 회로
|
|
US6537776B1
(en)
|
1999-06-14 |
2003-03-25 |
Diversa Corporation |
Synthetic ligation reassembly in directed evolution
|
|
US5789244A
(en)
|
1996-01-08 |
1998-08-04 |
Canji, Inc. |
Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
|
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
|
DE69733560T2
(de)
*
|
1996-03-04 |
2006-05-11 |
Scios Inc., Fremont |
TESTVERFAHREN UND REAGENZIEN ZUR QUANTIFIZIERUNG VON hBNP
|
|
EP0892643B2
(en)
|
1996-03-20 |
2009-09-02 |
Bristol-Myers Squibb Company |
Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
|
|
US6261552B1
(en)
|
1997-05-22 |
2001-07-17 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Herpes simplex virus vectors
|
|
AU3210997A
(en)
|
1996-05-24 |
1997-12-09 |
University Of Maryland At Baltimore |
Dna vaccines for eliciting a mucosal immune response
|
|
US5750356A
(en)
|
1996-05-31 |
1998-05-12 |
Anergen, Inc. |
Method for monitoring T cell reactivity
|
|
GB9619002D0
(en)
|
1996-09-11 |
1996-10-23 |
Oxford Biosciences Ltd |
Particle delivery
|
|
EP0987326A4
(en)
|
1996-07-11 |
2002-11-06 |
Takara Shuzo Co |
METHOD FOR PERFORMING A DIRECTED MUTAGENESIS
|
|
AU3980497A
(en)
|
1996-08-14 |
1998-03-06 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
A vector for polynucleotide vaccines
|
|
US6211160B1
(en)
|
1996-09-06 |
2001-04-03 |
The Trustees Of The University Of Pennsylvania |
Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
|
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
|
US6107477A
(en)
|
1996-09-26 |
2000-08-22 |
Aurora Biosciences Corporation |
Non-optimal Kozaks sequences
|
|
KR100620481B1
(ko)
|
1996-10-23 |
2006-09-06 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
개선된 백신
|
|
US7732129B1
(en)
|
1998-12-01 |
2010-06-08 |
Crucell Holland B.V. |
Method for the production and purification of adenoviral vectors
|
|
EP0968284B1
(en)
|
1996-11-20 |
2006-12-13 |
Introgen Therapeutics, Inc. |
An improved method for the production and purification of adenoviral vectors
|
|
HUP0001964A3
(en)
|
1997-01-29 |
2002-01-28 |
Cornell Res Foundation Inc Ith |
Multiple site delivery of adenoviral vector for the induction of angiogenesis
|
|
ZA98533B
(en)
*
|
1997-01-31 |
1999-07-22 |
Bristol Myers Squibb Co |
Soluble CTLA4 mutant molecules and uses thereof.
|
|
US5837283A
(en)
|
1997-03-12 |
1998-11-17 |
The Regents Of The University Of California |
Cationic lipid compositions targeting angiogenic endothelial cells
|
|
US6261281B1
(en)
|
1997-04-03 |
2001-07-17 |
Electrofect As |
Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
|
|
CN1198665C
(zh)
|
1997-04-03 |
2005-04-27 |
依莱克脱罗弗克脱联合股份有限公司 |
将药物和核酸导入骨骼肌的方法
|
|
US6225082B1
(en)
|
1997-05-09 |
2001-05-01 |
Research Corporation Technologies, Inc. |
Myelin basic protein MRNA transport and translation enhancer sequences
|
|
ATE252596T1
(de)
|
1997-06-06 |
2003-11-15 |
Dynavax Tech Corp |
Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon
|
|
AU8067698A
(en)
|
1997-06-09 |
1998-12-30 |
Genvec, Inc. |
Chimeric vectors comprising a phage packaging site and a portion derived from a genome of a eukaryotic virus
|
|
DE19729058A1
(de)
|
1997-07-08 |
1999-01-14 |
Sika Ag |
Verbundelement und Verfahren zu seiner Herstellung
|
|
US6165476A
(en)
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
|
US20010007860A1
(en)
|
1997-07-14 |
2001-07-12 |
Christopher W. Olsen |
Method of dna vaccination
|
|
WO1999008689A1
(en)
|
1997-08-21 |
1999-02-25 |
Powderject Vaccines, Inc. |
Mucosal immunization using particle-mediated delivery techniques
|
|
CA2304173A1
(en)
|
1997-09-23 |
1999-04-01 |
Genvec, Inc. |
Plasmids for construction of eukaryotic viral vectors
|
|
US5932445A
(en)
|
1997-11-07 |
1999-08-03 |
Incyte Pharmaceuticals, Inc. |
Signal peptide-containing proteins
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
MXPA00007893A
(es)
|
1998-02-11 |
2002-10-23 |
Maxygen Inc |
Direccion de vectores de vacunas geneticas.
|
|
US6087341A
(en)
|
1998-02-12 |
2000-07-11 |
The Board Of Trustees Of The Leland Standford Junior University |
Introduction of nucleic acid into skin cells by topical application
|
|
US5922576A
(en)
|
1998-02-27 |
1999-07-13 |
The John Hopkins University |
Simplified system for generating recombinant adenoviruses
|
|
WO1999047558A2
(en)
|
1998-03-19 |
1999-09-23 |
Heska Corporation |
T cell costimulatory proteins, sequences and uses thereof
|
|
US6121236A
(en)
|
1998-03-24 |
2000-09-19 |
The Children's Medical Center Corporation |
Multivalent ligands which modulate angiogenesis
|
|
EA200001096A1
(ru)
|
1998-04-22 |
2001-04-23 |
Джинвек, Инк. |
Способ обогащения раствора аденовируса, способ точного подсчета числа аденовирусных частиц в образце раствора (варианты) и способ очистки аденовируса из клеток, инфицированных аденовирусом
|
|
AU3739999A
(en)
|
1998-05-06 |
1999-11-23 |
Pharmacia & Upjohn Company |
Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate
|
|
US6436897B2
(en)
|
1998-06-01 |
2002-08-20 |
Celtrix Pharmaceuticals, Inc. |
Pharmaceutical formulations for IGF/IGFBP
|
|
US5965358A
(en)
|
1998-08-26 |
1999-10-12 |
Genvec, Inc. |
Method for assessing the relative purity of viral gene transfer vector stocks
|
|
US6455314B1
(en)
|
1998-09-11 |
2002-09-24 |
Genvec, Inc. |
Alternatively targeted adenovirus
|
|
US6800457B2
(en)
|
1998-09-22 |
2004-10-05 |
Bristol-Myers Squibb Company |
Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
|
|
US6521419B1
(en)
|
1998-09-22 |
2003-02-18 |
Kanakaraju Koduri |
Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
|
|
US6225113B1
(en)
|
1998-12-04 |
2001-05-01 |
Genvec, Inc. |
Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
|
|
US6225289B1
(en)
|
1998-12-10 |
2001-05-01 |
Genvec, Inc. |
Methods and compositions for preserving adenoviral vectors
|
|
EP3553085A1
(en)
|
1998-12-23 |
2019-10-16 |
Pfizer Inc |
Human momoclonal antibodies to ctla-4
|
|
WO2000039318A1
(en)
|
1998-12-31 |
2000-07-06 |
Chiron Corporation |
Compositions and methods for packaging of alphavirus vectors
|
|
CA2361421A1
(en)
|
1999-02-03 |
2000-08-10 |
Biosante Pharmaceuticals, Inc. |
Therapeutic calcium phosphate particles and methods of manufacture and use
|
|
US6281005B1
(en)
|
1999-05-14 |
2001-08-28 |
Copernicus Therapeutics, Inc. |
Automated nucleic acid compaction device
|
|
AU2001249380A1
(en)
|
2000-03-22 |
2001-11-07 |
Chiron Corporation |
Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
|
|
US6168941B1
(en)
|
2000-04-07 |
2001-01-02 |
Genvec, Inc. |
Method of producing adenoviral vector stocks
|
|
CA2407050A1
(en)
|
2000-04-25 |
2001-11-01 |
Chiron Corporation |
Alphavirus-based vectors for persistent infection
|
|
US20020058039A1
(en)
|
2000-04-27 |
2002-05-16 |
Coyne Michael J. |
Method of measuring the duration of adequate immune memory in companion animals
|
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
|
RU2283847C2
(ru)
*
|
2000-05-26 |
2006-09-20 |
Бристол-Маерс Сквибб Компани |
Растворимый мутантный ctla4 и его применение
|
|
US7094875B2
(en)
*
|
2000-06-23 |
2006-08-22 |
Maxygen, Inc. |
Co-stimulatory polypeptides
|
|
WO2002000897A2
(en)
|
2000-06-23 |
2002-01-03 |
Maxygen, Inc. |
Novel chimeric promoters
|
|
US7183376B2
(en)
*
|
2000-06-23 |
2007-02-27 |
Maxygen, Inc. |
Variant B7 co-stimulatory molecules
|
|
US20050154189A1
(en)
*
|
2000-06-23 |
2005-07-14 |
Maxygen Inc |
Novel co-stimulatory molecules
|
|
JP2004517806A
(ja)
|
2000-07-03 |
2004-06-17 |
ブリストル−マイヤーズ スクイブ カンパニー |
可溶性ｃｔｌａ４分子を使用するリウマチ疾患の処置方法
|
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
|
AU2001271839A1
(en)
*
|
2000-07-05 |
2002-01-14 |
Pharmacia And Upjohn Company |
Human ion channels
|
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
JP4837880B2
(ja)
|
2001-05-23 |
2011-12-14 |
ブリストル−マイヤーズ スクイブ カンパニー |
可溶性ｃｔｌａ４突然変異体分子を使って同種異系島移植片を保護する方法
|
|
FR2843396B1
(fr)
*
|
2002-08-07 |
2005-04-15 |
Bio Rad Pasteur |
Anticorps specifiques pour le diagnostic de l'insuffisance cardiaque
|
|
US7648962B2
(en)
*
|
2002-11-26 |
2010-01-19 |
Biocon Limited |
Natriuretic compounds, conjugates, and uses thereof
|
|
WO2004058944A2
(en)
|
2002-12-23 |
2004-07-15 |
Bristol-Myers Squibb Company |
Product quality enhancement in mammalian cell culture processes for protein production
|
|
NZ573652A
(en)
|
2003-08-04 |
2009-11-27 |
Bristol Myers Squibb Co |
Methods for treating cardiovascular disease using a soluble CTLA4 molecule
|
|
US7731965B2
(en)
*
|
2005-02-17 |
2010-06-08 |
Abbott Lab |
Human ring specific BNP antibodies
|
|
LT2586459T
(lt)
|
2005-03-25 |
2017-09-25 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonisto kompozicijos
|
|
MX2007012222A
(es)
|
2005-04-06 |
2007-12-06 |
Bristol Myers Squibb Co |
Metodo para tratamiento de trastornos inmunes asociados con trasplante de injerto con moleculas mutantes ctla4 solubles.
|
|
GB0620934D0
(en)
*
|
2006-10-20 |
2006-11-29 |
Cambridge Antibody Tech |
Protein variants
|
|
EP2612868B1
(en)
*
|
2007-11-01 |
2018-08-15 |
Astellas Pharma Inc. |
Immunosuppressive polypeptides and nucleic acids
|
|
US9405700B2
(en)
|
2010-11-04 |
2016-08-02 |
Sonics, Inc. |
Methods and apparatus for virtualization in an integrated circuit
|